论文部分内容阅读
本文研究了碳酸锂对毒性弥漫性甲状腺肿病人的疗效,并检测了治疗过程中T-淋巴细胞的改变。 15例毒性弥漫性甲状腺肿病人,甲状腺肿大Ⅰ～Ⅱ°者6例,Ⅲ°者9例。重症甲状腺毒症者3例,中度8例,轻度者4例。20例健康志愿者为对照组。碳酸锂用量:轻度患者每日0.9～1.2 g,中度患者每日1.2～1.5 g,重型病人每日1.5～1.8 g。疗程3～4个月。治疗前和治疗结束时采血检查甲状腺素和T-淋巴细胞指标(T-淋巴细胞绝对和相对含量、活性T-淋巴细胞含量及血清胸腺素活性)。治疗前病人T-淋巴细胞指标低于健康人的相应指标。碳酸锂治疗3～4周时,免疫
This article examines the efficacy of lithium carbonate in patients with toxic diffuse goiter and examines the changes in T-lymphocytes during treatment. 15 cases of diffuse diffuse goiter in patients with goiter Ⅰ ~ Ⅱ ° in 6 cases, Ⅲ ° in 9 cases. 3 cases of severe thyrotoxicosis, moderate in 8 cases, mild in 4 cases. Twenty healthy volunteers as control group. Lithium carbonate dosage: 0.9-1.2 g daily for mild patients, 1.2-1.5 g daily for moderate patients and 1.5-1.8 g daily for heavy patients. Course of 3 to 4 months. Blood levels of thyroxine and T-lymphocytes (absolute and relative levels of T-lymphocytes, active T-lymphocytes, and serum thymosin activity) were examined before treatment and at the end of treatment. T-lymphocyte index before treatment is lower than the corresponding indicators of healthy people. Lithium carbonate treatment of 3 to 4 weeks, immunization